We believe that people with migraine deserve to reclaim their life. Salvia BioElectronics is pioneering neuromodulation therapy aiming to transform the migraine treatment landscape.
Salvia BioElectronics has raised €53M across 1 funding round from 9 investors, most recently a Series B round in May 2025. Based in Eindhoven, Netherlands; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-05-27 | Series B |
| €53M |
| Brabant Development Agency (BOM),Dolby Family Ventures,EIC Fund,Inkef Capital,Innovation Industries,Invest-NL+3 more |
| View deal → |
